Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study

Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study

Background: Dupilumab is an IL-4Rα antibody approved for treatment of severe asthma. Real-world data on the continuation and cessation patterns of dupilumab and long-term treatment efficacy are scarce. Objective: We sought to analyze real-world, long-term treatment outcomes and to evaluate trajector...

Full description

Saved in:
Bibliographic Details
Main Authors: Carlo Mümmler, MD, Alexandra Lenoir, MD, Jeremias Götschke, MD, Michael Gerckens, MD, Merle Kaiser, MD, Moritz Kayser, MD, Nora Drick, MD, Hendrik Suhling, MD, Leonie Biener, MD, Carmen Pizarro, MD, Dirk Skowasch, MD, Nikolaus Kneidinger, MD, PhD, Jürgen Behr, MD, Katrin Milger, MD
Format: Article
Language:English
Published: Elsevier 2025-11-01
Series:Journal of Allergy and Clinical Immunology: Global
Subjects:
Severe asthma
dupilumab
long-term
antibody
real-world
Online Access:http://www.sciencedirect.com/science/article/pii/S2772829325001341
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2772829325001341

Similar Items